Distribution and characteristics of Escherichia coli clonal group A.
Among 1,102 recent Escherichia coli clinical isolates, clonal group A was identified in 17 of 20 (U.S. and non-U.S.) geographic locales, mainly among U.S. isolates (9% vs. 3%; p < 0.001) and those resistant to trimethoprim-sulfamethoxazole (10% vs. 1.7%; p < 0.001). The extensive antimicrobial resistance and virulence profiles of clonal group A may underlie its recent widespread emergence.
Johnson
James R
JR
Infectious Diseases (111F), Minneapolis VA Medical Center, 1 Veterans Drive, Minneapolis, MN 55417, USA. johns007@umn.edu
Murray
Andrew C
AC
Kuskowski
Michael A
MA
Schubert
Sören
S
Prère
Marie-Francoise
MF
Picard
Bertrand
B
Colodner
Raul
R
Raz
Raul
R
D000890:Anti-Infective Agents / Q000494:pharmacology*; D002648:Child; D021821:Communicable Diseases, Emerging / Q000453:epidemiology* / Q000382:microbiology; D024881:Drug Resistance, Bacterial; D004926:Escherichia coli / Q000145:classification* / Q000187:drug effects / Q000235:genetics / Q000472:pathogenicity; D004927:Escherichia coli Infections / Q000453:epidemiology* / Q000382:microbiology; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D010802:Phylogeny; D015995:Prevalence; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000494:pharmacology*; D014481:United States / Q000453:epidemiology; D014552:Urinary Tract Infections / Q000453:epidemiology* / Q000382:microbiology; D014774:Virulence
D000890:Anti-Infective Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination